Taieb and coworkers performed a phase III randomized trial to determine the prognostic and predictive value of primary tumor location according to BRAF, RAS and MSI status in patients with stage III colon cancer receiving adjuvant treatment with FOLFOX, with or without cetuximab, in stage III colorectal patients categorized according to primary tumor site (proximal or distal). Here, BRAF is linked to colonic neoplasm.